Pharmalot

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Medicare obesity drug coverage, a first-of-its-kind 340B analysis, and more

Pharmalot Ed Silverman

STAT Plus: Minnesota becomes first state to release report on 340B drug discount program for ‘safety-net’ hospitals

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Trump’s FDA pick, problems with a Merck asthma drug, and more

Pharmalot Ed Silverman

STAT Plus: Sanofi plans to change payment terms for 340B hospitals

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about picking an FDA chief, a menopause film controversy, and more

Pharmalot Ed Silverman

STAT Plus: A documentary about menopause has ‘misinformation’ and shouldn’t be used to educate docs, critics say

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Trump and tariff worries, PBM rules in New York, and more

Pharmalot Tara Bannow and Ed Silverman

STAT Plus: The health care industry is girding for Trump’s tariffs —and pushing hard for carveouts

Pharmalot Ed Silverman

STAT Plus: What records? Chinese company refuses to let FDA inspectors review documents or machinery

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Pfizer’s new R&D head, Merck and J&J job cuts in China, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more

Pharmalot Ed Silverman

STAT Plus: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about RFK Jr. and vaccines, obesity-drug prescribing for kids, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more

Pharmalot Ed Silverman

STAT Plus: FDA scolds Merz over ‘misleading’ Instagram posts featuring interior designer Nate Berkus

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more

Pharmalot Ed Silverman

STAT Plus: FDA is still struggling with a lack of inspectors, but doesn’t have a plan, watchdog finds

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an Amgen data controversy, J&J suing the feds, and more

Pharmalot Ed Silverman

STAT Plus: Johnson & Johnson sues Biden administration over payment terms for 340B hospitals

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA plans to ban a cold med; Eisai Alzheimer’s drug sales, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about RFK Jr. looking to shrink the FDA, an AstraZeneca exec held in China, and more

Pharmalot Ed Silverman

STAT Plus: AstraZeneca says China has detained a senior executive

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about compounded Wegovy, pharmacies suing GoodRx, and more

Pharmalot Ed Silverman

STAT Plus: Pharmacies sue GoodRx and PBMs over ‘illegal’ reimbursement fees